Drug Discovery
ByWhat broader implications does Zealand Pharma’s petrelintide trial setback raise for the GLP-1 obesity market?
Trial Context Recap ZUPREME-1 delivered 10.7% peak weight loss over 42 weeks across 493 patients, surpassing placebo but…
The $10B+ Pharma Titans of 2025: Fortress Builders or House of Cards?
In 2025, only nine pharmaceutical brands crossed the $10 billion revenue threshold, collectively generating $125B+ while representing 25% of global pharma sales—yet their…
How Does Eli Lilly Secure $100B+ Obesity Dominance Through 8 Triple/Triple+ Agonist Launches by 2030?
Eli Lilly establishes unrivaled obesity leadership through its 40 Phase 2/3 programs and 34 discovery-stage assets, commanding 60% US GLP-1 market share via Mounjaro/Zepbound ($39.5B 2025 revenue)…
How Does Bristol Myers Squibb Secure Multi-Billion Dollar Growth Through 8 Key Oncology Catalysts by 2030?
Bristol Myers Squibb strategically positions for next-decade dominance through its deep pipeline featuring 5 multi-billion-dollar assets (pumitamig, iberdomide, mezigdomide, milvexian, Cobenfy) across…
AI in Life Sciences: A Multi-Billion Dollar Transformation Reshaping Drug Discovery and Healthcare
Artificial intelligence is rapidly becoming one of the most transformative forces in the life sciences industry. Global investment…
Strategic Industry Analysis: What the Biggest Biopharma Deals of 2025 Reveal About the Future of Drug Innovation
The global biopharmaceutical industry experienced a powerful wave of strategic dealmaking in 2025 as major pharmaceutical companies accelerated…
